HC Wainwright Has Optimistic Outlook of IOVA Q2 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Equities researchers at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a research note issued on Thursday, May 7th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of ($0.16) for the quarter, up from their previous estimate of ($0.20). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.72) EPS and FY2027 earnings at ($0.46) EPS.

Several other brokerages also recently issued reports on IOVA. Citizens Jmp raised Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 target price on the stock in a research note on Tuesday, March 3rd. Chardan Capital cut their price target on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, May 7th. UBS Group raised their price target on Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Monday, April 6th. Finally, The Goldman Sachs Group restated a “sell” rating and set a $2.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.43.

Iovance Biotherapeutics Trading Up 2.2%

Shares of IOVA opened at $3.70 on Tuesday. The business’s 50 day moving average is $3.80 and its 200 day moving average is $2.96. The company has a market capitalization of $1.65 billion, a PE ratio of -3.89 and a beta of 0.69. Iovance Biotherapeutics has a 12-month low of $1.64 and a 12-month high of $5.63.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). The company had revenue of $71.43 million for the quarter, compared to the consensus estimate of $77.84 million. Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.The firm’s quarterly revenue was up 44.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.36) EPS.

Hedge Funds Weigh In On Iovance Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Iovance Biotherapeutics by 13.1% in the 4th quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock worth $74,275,000 after purchasing an additional 3,148,096 shares during the period. State Street Corp boosted its holdings in shares of Iovance Biotherapeutics by 51.5% in the 4th quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock worth $55,041,000 after purchasing an additional 6,851,486 shares during the period. Invenomic Capital Management LP boosted its holdings in shares of Iovance Biotherapeutics by 13.5% in the 4th quarter. Invenomic Capital Management LP now owns 11,959,505 shares of the biotechnology company’s stock worth $32,649,000 after purchasing an additional 1,417,897 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Iovance Biotherapeutics by 30.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 8,607,564 shares of the biotechnology company’s stock worth $23,499,000 after purchasing an additional 2,032,062 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Iovance Biotherapeutics by 16.4% in the 4th quarter. Geode Capital Management LLC now owns 7,991,640 shares of the biotechnology company’s stock worth $21,821,000 after purchasing an additional 1,123,337 shares during the period. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical?stage biotechnology company specializing in the development and commercialization of tumor?infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN?144), is an autologous TIL therapy in late?stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next?generation TIL programs such as LN?145 for cervical and other human papillomavirus (HPV)?related cancers, as well as exploratory studies in head and neck, non?small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor?reactive lymphocytes.